Therapeutic levels are achieved in 24 hours and maintained for 28 days10
Mean serum lanreotide concentration increases following a single dose of Somatuline® Depot (lanreotide) Injection10*
The steady-state values of Cmin, Cmax, and AUCt increase in a dose-dependent, linear manner10
Lanreotide has a high affinity for the somatostatin receptor subtypes (SSTR) 2 and 51,12
Clinical studies show similar potency and selectivity for SSTR 2 and SSTR 5 between lanreotide and octreotide.5
Activity at SSTR 2 and SSTR 5 is the primary mechanism believed responsible for GH inhibition.1
* From a phase II, randomized, double-blind study, during which 18 patients with acromegaly underwent a washout period of up to six weeks and then received Somatuline® Depot (lanreotide) Injection 60 mg, 90 mg, or 120 mg for four fixed injections at 28-day intervals. Chart adapted from Bronstein M, et al.10
Affinity measured as Ki (nM), where Ki is an inhibitory constant, a measure of affinity. The lower the number, the higher the affinity.
